{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:42:36Z","timestamp":1773272556118,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.beem.2015.01.006","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T21:10:30Z","timestamp":1422047430000},"page":"183-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["The role of antibodies in enzyme treatments and therapeutic strategies"],"prefix":"10.1016","volume":"29","author":[{"given":"Brian W.","family":"Bigger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Saif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2015.01.006_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.3021","article-title":"The cellular pathology of lysosomal diseases","volume":"226","author":"Cox","year":"2011","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.beem.2015.01.006_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.beem.2015.01.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K","article-title":"Human immune response to recombinant human proteins","volume":"90","author":"Porter","year":"2001","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.beem.2015.01.006_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1532\/IJH97.06019","article-title":"Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data","volume":"84","author":"Yoshioka","year":"2006","journal-title":"Int J Hematol"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2015.01.006_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/diacare.5.2.S171","article-title":"Decrease of circulating insulin antibodies in two patients treated with continuous subcutaneous infusion of human insulin (recombinant DNA)","volume":"5","author":"Spijker","year":"1982","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2015.01.006_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00284452","article-title":"Immunogenicity of recombinant DNA human insulin","volume":"25","author":"Fineberg","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2015.01.006_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0168-8227(86)80068-7","article-title":"Immunogenicity of biosynthetic human insulin. Humoral immune response in diabetic patients beginning insulin treatment and in patients previously treated with other insulins","volume":"2","author":"Di Mario","year":"1986","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2015.01.006_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000182380","article-title":"Immunogenicity of a mammalian cell-derived recombinant human growth hormone preparation during long-term treatment","volume":"37","author":"Zeisel","year":"1992","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2015.01.006_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-4652(199711)173:2<219::AID-JCP25>3.0.CO;2-9","article-title":"Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum","volume":"173","author":"Laricchia-Robbio","year":"1997","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.beem.2015.01.006_bib10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/clinchem\/43.5.848","article-title":"Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance","volume":"43","author":"Urra","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.beem.2015.01.006_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(86)90013-6","article-title":"Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A)","volume":"80","author":"Spiegel","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2015.01.006_bib12","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3324\/haematol.2011.058644","article-title":"Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy","volume":"97","author":"Saif","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beem.2015.01.006_bib13","first-page":"443","article-title":"Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders","volume":"105","author":"Richards","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"Suppl. 6","key":"10.1016\/j.beem.2015.01.006_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.beem.2015.01.006_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.beem.2015.01.006_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibtech.2006.04.001","article-title":"Scientific and regulatory considerations on the immunogenicity of biologics","volume":"24","author":"Shankar","year":"2006","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.beem.2015.01.006_bib18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jpba.2011.03.038","article-title":"Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics","volume":"55","author":"Gupta","year":"2011","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.beem.2015.01.006_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease","volume":"289","author":"Brady","year":"1973","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.01.006_bib20","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage- targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.01.006_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0022-1759(91)90400-A","article-title":"Gaucher's disease: lack of antibody response in 12 patients following repeated intravenous infusions of mannose terminal glucocerebrosidase","volume":"137","author":"Murray","year":"1991","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.beem.2015.01.006_bib22","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beem.2015.01.006_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib24","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.beem.2015.01.006_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1079-9796(03)00012-3","article-title":"Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies","volume":"30","author":"Zhao","year":"2003","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0027-5107(01)00232-9","article-title":"Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase","volume":"483","author":"Germain","year":"2001","journal-title":"Mutat Res"},{"key":"10.1016\/j.beem.2015.01.006_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","article-title":"Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase","volume":"90","author":"Ponce","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beem.2015.01.006_bib28","first-page":"15","article-title":"Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting","volume":"40","author":"Fabbro","year":"1987","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2015.01.006_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.beem.2015.01.006_bib30","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, et al. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J\u00a0Inherit Metab Dis [Epub ahead of print, PMID: 24715333]"},{"key":"10.1016\/j.beem.2015.01.006_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","volume":"160C","author":"Bali","year":"2012","journal-title":"Am J Med Genet Part C Semin Med Genet"},{"key":"10.1016\/j.beem.2015.01.006_bib33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A\u00a0randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.01.006_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib35","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2015.01.006_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.01.006_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2015.01.006_bib38","series-title":"A\u00a0biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","author":"Lee","year":"2005"},{"key":"10.1016\/j.beem.2015.01.006_bib39","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u00a0mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2015.01.006_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib41","first-page":"1","article-title":"A\u00a0revised home treatment algorithm for Fabry disease: influence of antibody formation","author":"Smid","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2015.01.006_bib43","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2015.01.006_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib45","unstructured":"FDA briefing document Fabrazyme."},{"key":"10.1016\/j.beem.2015.01.006_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2013role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.beem.2015.01.006_bib49","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase a in fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2015.01.006_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A\u00a0retrospective analysis of the potential impact of IgG antibodies to agalsidase \u03b2 on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2015.01.006_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"Suppl. B","key":"10.1016\/j.beem.2015.01.006_bib54","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0149-2918(08)80041-0","article-title":"The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative","volume":"30","author":"Schellekens","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.beem.2015.01.006_bib55","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.1073\/pnas.91.26.12937","article-title":"Enzyme replacement in a canine model of Hurler syndrome","volume":"91","author":"Shull","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2015.01.006_bib56","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2015.01.006_bib57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.beem.2015.01.006_bib58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2009.07.001","article-title":"Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa","volume":"98","author":"Lipinski","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib59","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2015.01.006_bib60","first-page":"2686","article-title":"Immune response hinders therapy for lysosomal storage diseases","volume":"118","author":"Ponder","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2015.01.006_bib61","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.beem.2015.01.006_bib62","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(09)61070-9","article-title":"Bone-marrow transplantation in non-malignant disease","volume":"374","author":"Wynn","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2015.01.006_bib63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10545-010-9254-8","article-title":"Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases","volume":"34","author":"Langford-Smith","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/01913121003648485","article-title":"Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: effects of enzyme replacement therapy and hematopoietic cell transplantation","volume":"34","author":"Cox-Brinkman","year":"2010","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.beem.2015.01.006_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","article-title":"Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy","volume":"14","author":"Langereis","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A\u00a0phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2015.01.006_bib67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A\u00a0phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2015.01.006_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10545-011-9369-6","article-title":"Longitudinal observations of serum heparin cofactor II-thrombin complex in treated mucopolysaccharidosis I and II patients","volume":"35","author":"Clarke","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib71","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"STRIVE Investigators","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib72","first-page":"1","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with morquio a syndrome: results from MOR-004, a phase III trial","author":"Schweighardt","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.beem.2015.01.006_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-8-51","article-title":"Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase","volume":"8","author":"Brands","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2015.01.006_bib75","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1681\/ASN.2013030290","article-title":"Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy","volume":"25","author":"Debiec","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.beem.2015.01.006_bib76","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.beem.2015.01.006_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2015.01.006_bib78","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beem.2015.01.006_bib79","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1160\/TH14-01-0078","article-title":"Rituximab for treatment of inhibitors in haemophilia A","volume":"112","author":"Leissinger","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.beem.2015.01.006_bib80","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.01.006_bib81","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2012","journal-title":"Genet Med"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X15000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X15000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:48:47Z","timestamp":1761497327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X15000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1521690X15000184"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2015.01.006","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of antibodies in enzyme treatments and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2015.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}